GlassScriptPhysician profile
Dale Fuller
NPI 1255462735
$12,585.88
in general payments reported to CMS, 2019-2025
39 companies · $3,638 in 2025
The $3,638 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,261 · 2022: $2,274 · 2023: $2,693 · 2024: $2,720 · 2025: $3,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,503 · Consulting Fee: $1,215 · Travel and Lodging: $193 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,503.09 |
| Consulting Fee | $1,215.00 |
| Travel and Lodging | $192.83 |
| Education | $139.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,952.14 | 2021-2025 | |
| Madrigal Pharmaceuticals | $1,863.48 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $1,117.23 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $981.67 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $750.53 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $617.46 | 2021-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $551.29 | 2021-2024 | Stelara, Remicade, Tremfya |
| Pfizer INC. | $415.51 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $375.93 | 2024-2025 | Iqirvo, Bylvay |
| Genzyme Corporation | $357.58 | 2022-2025 | |
| Celgene Corporation | $333.02 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $332.97 | 2022-2025 | Ocaliva |
| Braintree Laboratories, INC. | $291.28 | 2021-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $277.02 | 2021-2025 | Linzess |
| Redhill Biopharma INC. | $228.40 | 2021-2023 | Talicia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $207.08 | 2021-2024 | Dificid, Zinplava |
| E.R. Squibb & Sons, L.L.C. | $205.55 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $204.26 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $177.54 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $157.13 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $156.45 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $153.98 | 2023-2025 | Dupixent |
| Organon LLC | $137.93 | 2021-2024 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $99.61 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $93.67 | 2021-2023 | |
| Evoke Pharma, INC. | $64.03 | 2023-2025 | Gimoti |
| Novo Nordisk INC | $58.57 | 2023-2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $54.35 | 2021-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $53.47 | 2023-2024 | Idacio |
| Amgen INC. | $53.22 | 2023 | Amjevita, Avsola |
| Enterra Medical, INC. | $50.50 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.88 | 2023-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $46.12 | 2024-2025 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $37.34 | 2021-2022 | |
| Sandoz INC. | $20.84 | 2023 | Hyrimoz |
| Coloplast Corp | $17.23 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.58 | 2023 | |
| Celltrion USA INC. | $13.34 | 2023 | Yuflyma |
| Medtronic, INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.